Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

Ravi Salgia, MD, PhD
Published: Monday, Feb 19, 2018



Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

The phase I clinical trial that investigated crizotinib (Xalkori) was initially designed to examine the compound as a MET inhibitor. Investigators later realized that it was also an effective ALK inhibitor, Salgia says. The drug was later approved by the FDA because of its durable progression-free survival in third-line, fourth-line, and fifth-line therapies.

There are other tyrosine-kinase inhibitors for ALK-positive patients, such as ceritinib (Zykadia), brigatinib (Alunbrig), and alectinib (Alecensa). Now, researchers are looking at how to optimally sequence these agents.
 
SELECTED
LANGUAGE


Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

The phase I clinical trial that investigated crizotinib (Xalkori) was initially designed to examine the compound as a MET inhibitor. Investigators later realized that it was also an effective ALK inhibitor, Salgia says. The drug was later approved by the FDA because of its durable progression-free survival in third-line, fourth-line, and fifth-line therapies.

There are other tyrosine-kinase inhibitors for ALK-positive patients, such as ceritinib (Zykadia), brigatinib (Alunbrig), and alectinib (Alecensa). Now, researchers are looking at how to optimally sequence these agents.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x